These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35058439)

  • 1. From prodrug to pro-prodrug: hypoxia-sensitive antibody-drug conjugates.
    Wang Y; Xiao D; Li J; Fan S; Xie F; Zhong W; Zhou X; Li S
    Signal Transduct Target Ther; 2022 Jan; 7(1):20. PubMed ID: 35058439
    [No Abstract]   [Full Text] [Related]  

  • 2. Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy.
    Joubert N; Denevault-Sabourin C; Bryden F; Viaud-Massuard MC
    Eur J Med Chem; 2017 Dec; 142():393-415. PubMed ID: 28911823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody-Drug Conjugates.
    Pei Z; Chen C; Chen J; Cruz-Chuh JD; Delarosa R; Deng Y; Fourie-O'Donohue A; Figueroa I; Guo J; Jin W; Khojasteh SC; Kozak KR; Latifi B; Lee J; Li G; Lin E; Liu L; Lu J; Martin S; Ng C; Nguyen T; Ohri R; Lewis Phillips G; Pillow TH; Rowntree RK; Stagg NJ; Stokoe D; Ulufatu S; Verma VA; Wai J; Wang J; Xu K; Xu Z; Yao H; Yu SF; Zhang D; Dragovich PS
    Mol Pharm; 2018 Sep; 15(9):3979-3996. PubMed ID: 30040421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy.
    Fang L; Sun D
    Drug Metab Dispos; 2008 Jun; 36(6):1153-65. PubMed ID: 18356268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo comparison of a randomly coupled antibody fragment-enzyme conjugate with a site-specific conjugate.
    Werlen RC; Offord RE; Blakey DC; East SJ; Melton RG; Rose K
    Biomed Pept Proteins Nucleic Acids; 1995; 1(5):251-4. PubMed ID: 9575348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of acivicin prodrugs as antibody conjugates.
    Antczak C; Bauvois B; Monneret C; Florent JC
    J Control Release; 2001 Jul; 74(1-3):255-7. PubMed ID: 11489503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiotherapy activates picolinium prodrugs in tumours.
    Fu Q; Gu Z; Shen S; Bai Y; Wang X; Xu M; Sun P; Chen J; Li D; Liu Z
    Nat Chem; 2024 Aug; 16(8):1348-1356. PubMed ID: 38561425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD147 Monoclonal Antibody Targeted Reduction-Responsive Camptothecin Polyphosphoester Nanomedicine for Drug Delivery in Hepatocellular Carcinoma Cells.
    Tian H; Huang Y; He J; Zhang M; Ni P
    ACS Appl Bio Mater; 2021 May; 4(5):4422-4431. PubMed ID: 35006854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib.
    Bielec B; Schueffl H; Terenzi A; Berger W; Heffeter P; Keppler BK; Kowol CR
    Bioorg Chem; 2020 Jun; 99():103778. PubMed ID: 32229347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-specific novel taxoid-monoclonal antibody conjugates.
    Ojima I; Geng X; Wu X; Qu C; Borella CP; Xie H; Wilhelm SD; Leece BA; Bartle LM; Goldmacher VS; Chari RV
    J Med Chem; 2002 Dec; 45(26):5620-3. PubMed ID: 12477344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymeric anticancer drugs with pH-controlled activation.
    Ulbrich K; Subr V
    Adv Drug Deliv Rev; 2004 Apr; 56(7):1023-50. PubMed ID: 15066758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-Prodrug Conjugates with KSP Inhibitors and Legumain-Mediated Metabolite Formation.
    Lerchen HG; Stelte-Ludwig B; Berndt S; Sommer A; Dietz L; Rebstock AS; Johannes S; Marx L; Jörißen H; Mahlert C; Greven S
    Chemistry; 2019 Jun; 25(35):8208-8213. PubMed ID: 30869180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemo-immunotherapy with doxorubicin prodrug and erythrocyte membrane-enveloped polymer nano-vaccine enhances antitumor activity.
    Bao Y; Hu Q; Wang X; Feng X; He Y; Guo Y; Fu D
    Biomed Pharmacother; 2020 Sep; 129():110377. PubMed ID: 32554247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel hypoxia-targeting Pt(iv) prodrugs.
    Xu Z; Zhao J; Gou S; Xu G
    Chem Commun (Camb); 2017 Mar; 53(26):3749-3752. PubMed ID: 28303266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An azobenzene-based heteromeric prodrug for hypoxia-activated chemotherapy by regulating subcellular localization.
    Li S; Jiang X; Zheng R; Zuo S; Zhao L; Fan G; Fan J; Liao Y; Yu X; Cheng H
    Chem Commun (Camb); 2018 Jul; 54(57):7983-7986. PubMed ID: 29963672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors.
    de Groot FM; Damen EW; Scheeren HW
    Curr Med Chem; 2001 Jul; 8(9):1093-122. PubMed ID: 11472243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and Evaluation of a CBZ-AAN-Dox Prodrug and its in vitro Effects on SiHa Cervical Cancer Cells Under Hypoxic Conditions.
    Chen H; Liu X; Clayman ES; Shao F; Xiao M; Tian X; Fu W; Zhang C; Ruan B; Zhou P; Liu Z; Wang Y; Rui W
    Chem Biol Drug Des; 2015 Oct; 86(4):589-98. PubMed ID: 25619622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzymatic activation of indolequinone-substituted 5-fluorodeoxyuridine prodrugs in hypoxic cells.
    Jiho Y; Kurihara R; Kawai K; Yamada H; Uto Y; Tanabe K
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1304-1307. PubMed ID: 30975626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators.
    Wilson WR; Stribbling SM; Pruijn FB; Syddall SP; Patterson AV; Liyanage HD; Smith E; Botting KJ; Tercel M
    Mol Cancer Ther; 2009 Oct; 8(10):2903-13. PubMed ID: 19808982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
    Martin J; Stribbling SM; Poon GK; Begent RH; Napier M; Sharma SK; Springer CJ
    Cancer Chemother Pharmacol; 1997; 40(3):189-201. PubMed ID: 9219501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.